4.5 Article

Regulation of B cell receptor signalling by Epstein-Barr virus nuclear antigens

期刊

BIOCHEMICAL JOURNAL
卷 479, 期 23, 页码 2395-2417

出版社

PORTLAND PRESS LTD
DOI: 10.1042/BCJ20220417

关键词

-

资金

  1. Chancellor's Research International Scholarship, University of Sussex
  2. Blood Cancer UK [15024]
  3. Biotechnology and Biological Sciences Research Council

向作者/读者索取更多资源

The Epstein-Barr virus (EBV), associated with cancer, manipulates the B cell receptor signaling pathway to control cell growth and survival. EBV transcription factors EBNA2, 3A, 3B, and 3C were found to bind to genomic sites around B cell receptor pathway genes, regulating their expression and affecting B cell receptor signaling. EBNA2 and EBNA3 predominantly repress the expression of B cell receptor pathway genes and target common genes. EBNA2 and at least one EBNA3 protein repress the central components of the B cell receptor pathway and downstream genes. This study reveals a mechanism through which EBV controls the growth and survival of infected B cells and maintains viral latency.
The cancer-associated Epstein-Barr virus (EBV) latently infects and immortalises B lymphocytes. EBV latent membrane protein 2A and EBV-encoded microRNAs are known to manipulate B cell receptor signalling to control cell growth and survival and suppress lytic replication. Here, we show that the EBV transcription factors EBNA2, 3A, 3B and 3C bind to genomic sites around multiple B cell receptor (BCR) pathway genes, regulate their expression and affect BCR signalling. EBNA2 regulates the majority of BCR pathway genes associated with binding sites, where EBNA3 proteins regulate only 42% of targets predicted by binding. Both EBNA2 and 3 proteins predominantly repress BCR pathway gene expression and target some common genes. EBNA2 and at least one EBNA3 protein repress the central BCR components CD79A and CD79B and the downstream genes BLNK, CD22, CD72, NFATC1, PIK3CG and RASGRP3. Studying repression of CD79B, we show that EBNA2 decreases transcription by disrupting binding of Early B cell Factor-1 to the CD79B promoter. Consistent with repression of BCR signalling, we demonstrate that EBNA2 and EBNA3 proteins suppress the basal or active BCR signalling that culminates in NFAT activation. Additionally, we show that EBNA2, EBNA3A and EBNA3C expression can result in reductions in the active serine 473 phosphorylated form of Akt in certain cell contexts, consistent with transcriptional repression of the PI3K-Akt BCR signalling arm. Overall, we identify EBNA2, EBNA3A and EBNA3C-mediated transcription control of BCR signalling as an additional strategy through which EBV may control the growth and survival of infected B cells and maintain viral latency.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据